Pfizer Lipitor Plan Might Not Be ‘Worth It,’ Watson CEO Says

Pfizer Inc.’s strategy to keep its market share of cholesterol pill Lipitor may boost revenue without aiding profit, said the chief executive officer of Watson Pharmaceuticals Inc., the drugmaker’s partner on the medicine’s generic version.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.